Breakthrough siRNA Drug SNS812 for COVID-19 Selected for Prestigious ATS 2025 Presentation
Key Insights
Oneness Biotech (search) and Microbio Shanghai's SNS812, the world's first fully modified siRNA drug administered via aerosol inhalation, has been selected for oral presentation at the 2025 ATS International Conference.
Phase II clinical trial results demonstrate SNS812 significantly reduces SARS-CoV-2 (search) viral load, accelerates symptom resolution, and shortens recovery time for smell and taste loss, with excellent safety profile.
The selection for the conference's highest-tier Mini Symposium format validates the companies' technological platform in nucleic acid drug development and their innovative approach to precision antiviral therapy.
The innovative broad-spectrum antiviral siRNA drug SNS812, co-developed by Oneness Biotech (search) and Microbio (Shanghai) (search), has been selected for oral presentation at the prestigious 2025 American Thoracic Society (ATS) International Conference, scheduled for May 16-21 in San Francisco. This selection highlights the drug's promising clinical outcomes in COVID-19 (search) treatment and represents significant recognition for the companies' nucleic acid drug development platform.
SNS812 stands as the world's first fully modified siRNA drug administered via aerosol inhalation that has been clinically validated. The drug has demonstrated potent broad-spectrum inhibitory activity against the SARS-CoV-2 (search) virus in clinical trials.
Groundbreaking Phase II Results
Phase II clinical trial data reveals that SNS812 delivers multiple therapeutic benefits for COVID-19 (search) patients. The drug significantly reduces viral load while accelerating the resolution of key respiratory symptoms, particularly shortness of breath. Notably, the treatment effectively shortens recovery time for smell and taste loss—symptoms that can persist long after initial infection.
These clinical outcomes suggest SNS812 has strong potential for preventing progression to severe disease while offering neuroprotective effects. The drug has also demonstrated an excellent safety and tolerability profile, with no serious adverse events reported during trials, positioning it as a promising candidate for inhalable broad-spectrum COVID-19 (search) therapy.
Dr. Wei Chen, Chief Scientific Officer at Oneness Biotech (search), stated, "The selection of SNS812 for presentation at ATS 2025 validates our approach to targeting viral replication through RNA interference. The aerosol delivery method allows direct administration to the primary site of infection, maximizing efficacy while minimizing systemic exposure."
Elite Recognition at ATS Conference
The presentation will be delivered in a Mini Symposium, the highest-tier session format at the ATS conference. This premier platform is reserved exclusively for studies demonstrating exceptional scientific originality, clinical significance, and contributions to global health. Selection requires passing through rigorous scientific review.
The ATS International Conference is one of the world's most prominent academic events in pulmonary diseases, critical care, and sleep medicine. The 2025 conference at San Francisco's Moscone Center is expected to attract over 14,000 medical experts, clinical researchers, and industry leaders globally.
Innovative siRNA Technology Platform
SNS812 represents a significant advancement in siRNA drug development. Small interfering RNA (siRNA) therapeutics work by selectively silencing disease-causing genes, offering a highly targeted approach to treatment.
"What makes SNS812 unique is its fully modified structure and specialized delivery system," explained Dr. Li Zhang, Head of R&D at Microbio (Shanghai) (search). "The modifications enhance stability and cellular uptake, while the aerosol formulation ensures direct delivery to the respiratory tract—the primary site of SARS-CoV-2 (search) infection."
The selection of SNS812 for the ATS conference affirms international recognition of both companies' technological platform in nucleic acid drug development and their innovative capabilities in precision antiviral therapy.
Future Development and Commercial Potential
Oneness Biotech (search) and Microbio (Shanghai) (search) are actively advancing global clinical development and licensing collaborations for SNS812, accelerating its path to commercialization. The companies are also exploring expanded applications of their siRNA platform across major infectious diseases and global public health challenges.
Beyond SNS812, Microbio's pipeline includes SNS851 targeting obesity (search) and metabolic dysfunction-associated steatohepatitis (MASH (search)), expected to enter clinical trials later in 2025, and SNS813 (search), designed for broad-spectrum inhibition of influenza viruses. The company is also developing precision-targeted nucleic acid antimicrobials against pathogenic bacteria.
Industry analysts note that the global market for RNA therapeutics is projected to grow significantly in the coming years, with respiratory applications representing a particularly promising segment. The successful development of SNS812 could position Oneness Biotech (search) and Microbio (Shanghai) (search) as leaders in this expanding field.
Advancing Nucleic Acid Therapeutics
Oneness Biotech (search), a Taiwan-based biopharmaceutical company, has established a comprehensive drug development platform with solid regulatory expertise. Its previous successes include ON101, a solution for chronic wound care, and FB825, an antibody drug for atopic dermatitis (search).
Microbio (Shanghai) (search), a member of the Microbio Group, specializes in innovative small nucleic acid drugs with an integrated R&D platform encompassing sequence design, chemical modification, and drug delivery systems. The company holds multiple core patents in the field.
The collaboration between these companies represents a significant step forward in the development of nucleic acid therapeutics, potentially offering new solutions for respiratory viral infections and other major health challenges.